Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma : an analysis from the OnCovid registry
© The Author(s), 2024..
Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population.
Methods: We described COVID-19 morbidity and mortality among patients with STS across 'Omicron' (15 December 2021-31 January 2022), 'Pre-vaccination' (27 February 2020-30 November 2020), and 'Alpha-Delta' phase (01 December 2020-14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders.
Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18-92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis.
Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Therapeutic advances in medical oncology - 16(2024) vom: 03., Seite 17588359231225028 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 10.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/17588359231225028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367398281 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367398281 | ||
| 003 | DE-627 | ||
| 005 | 20240210233144.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/17588359231225028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1287.xml |
| 035 | |a (DE-627)NLM367398281 | ||
| 035 | |a (NLM)38249336 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vincenzi, Bruno |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma |b an analysis from the OnCovid registry |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 10.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s), 2024. | ||
| 520 | |a Background: To date, limited evidence exists on the impact of COVID-19 in patients with soft tissue sarcoma (STS), nor about the impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in this specific population | ||
| 520 | |a Methods: We described COVID-19 morbidity and mortality among patients with STS across 'Omicron' (15 December 2021-31 January 2022), 'Pre-vaccination' (27 February 2020-30 November 2020), and 'Alpha-Delta' phase (01 December 2020-14 December 2021) using OnCovid registry participants (NCT04393974). Case fatality rate at 28 days (CFR28) and COVID-19 severity were also described according to the SARS-CoV-2 vaccination status, while the impact of the receipt of cytotoxic chemotherapy within 4 weeks prior to COVID-19 on clinical outcomes was assessed with Inverse Probability of Treatment Weighting (IPTW) models adjusted for possible confounders | ||
| 520 | |a Results: Out of 3820 patients, 97 patients with STS were included. The median age at COVID-19 diagnosis was 56 years (range: 18-92), with 65 patients (67%) aged < 65 years and most patients had a low comorbidity burden (65, 67.0%). The most frequent primary tumor sites were the abdomen (56.7%) and the gynecological tract (12.4%). In total, 36 (37.1%) patients were on cytotoxic chemotherapy within 4 weeks prior to COVID-19. The overall CFR28 was 25.8%, with 38% oxygen therapy requirement, 34% rate of complications, and 32.3% of hospitalizations due to COVID-19. CFR28 (29.5%, 21.4%, and 12.5%) and all indicators of COVID-19 severity demonstrated a trend toward a numerical improvement across the pandemic phases. Similarly, vaccinated patients demonstrated numerically improved CFR28 (16.7% versus 27.7%) and COVID-19 morbidity compared with unvaccinated patients. Patients who were on chemotherapy experienced comparable CFR28 (19.4% versus 26.0%, p = 0.4803), hospitalizations (50.0% versus 44.4%, p = 0.6883), complication rates (30.6% versus 34.0%, p = 0.7381), and oxygen therapy requirement (28.1% versus 40.0%, p = 0.2755) compared to those who were not on anticancer therapy at COVID-19, findings further confirmed by the IPTW-fitted multivariable analysis | ||
| 520 | |a Conclusion: In this study, we demonstrate an improvement in COVID-19 outcomes in patients with STS over time. Recent exposure to chemotherapy does not impact COVID-19 morbidity and mortality and SARS-CoV-2 vaccination confers protection against adverse outcomes from COVID-19 in this patient population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a sarcoma | |
| 650 | 4 | |a soft tissue sarcoma | |
| 650 | 4 | |a vaccines | |
| 700 | 1 | |a Cortellini, Alessio |e verfasserin |4 aut | |
| 700 | 1 | |a Mazzocca, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Romandini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Aguilar-Company, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Camps, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Valverde Morales, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Eremiev-Eremiev, Simeon |e verfasserin |4 aut | |
| 700 | 1 | |a Tondini, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Brunet, Joan |e verfasserin |4 aut | |
| 700 | 1 | |a Bertulli, Rossella |e verfasserin |4 aut | |
| 700 | 1 | |a Provenzano, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Bower, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Generali, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Salazar, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Sureda, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, Aleix |e verfasserin |4 aut | |
| 700 | 1 | |a Vasiliki, Michalarea |e verfasserin |4 aut | |
| 700 | 1 | |a Van Hemelrijck, Mieke |e verfasserin |4 aut | |
| 700 | 1 | |a Sita-Lumsden, Ailsa |e verfasserin |4 aut | |
| 700 | 1 | |a Bertuzzi, Alexia |e verfasserin |4 aut | |
| 700 | 1 | |a Rossi, Sabrina |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Amanda |e verfasserin |4 aut | |
| 700 | 1 | |a Grosso, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Alvin J X |e verfasserin |4 aut | |
| 700 | 1 | |a Murphy, Cian |e verfasserin |4 aut | |
| 700 | 1 | |a Belessiotis, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Mukherjee, Uma |e verfasserin |4 aut | |
| 700 | 1 | |a Pommeret, Fanny |e verfasserin |4 aut | |
| 700 | 1 | |a Loizidou, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gaidano, Gianluca |e verfasserin |4 aut | |
| 700 | 1 | |a Dettorre, Gino M |e verfasserin |4 aut | |
| 700 | 1 | |a Grisanti, Salvatore |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Fulgenzi, Claudia A M |e verfasserin |4 aut | |
| 700 | 1 | |a Gennari, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Napolitano, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Pinato, David J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic advances in medical oncology |d 2009 |g 16(2024) vom: 03., Seite 17588359231225028 |w (DE-627)NLM19877978X |x 1758-8340 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2024 |g day:03 |g pages:17588359231225028 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/17588359231225028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2024 |b 03 |h 17588359231225028 | ||